How Incarceration Raises Risk of Cancer Diagnosis and Death—Even After Release
The United States has one of the highest incarceration rates in the world, with nearly 2 million people in the criminal justice system facing potential barriers to accessing timely, quality care. Now, Yale researchers are finding that individuals with a history of incarceration are more likely to be diagnosed with cancer and are less likely to survive the disease.
Estimating the Environmental Impact of Certain Prostate Cancer Procedures
Michael Leapman, MD, MHS, and his research team produce never-before figures focused on the prostate biopsy and/or MRI. Learn what they're asking more physicians to consider when it comes to patient care and environmental impact.
Older Patients Left Behind in Progress Against Lung Cancer, Yale Study Shows
Although widespread use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer has led to meaningful improvements in survival in younger patients, older patients have not experienced similar survival benefits, new research from Yale Cancer Center shows. The study was published in JAMA Oncology.
Survival gains with checkpoint inhibitors differ ‘drastically’ between age groups in NSCLC
Despite significantly extending survival for younger adults with advanced non-small cell lung cancer, immune checkpoint inhibitors have conferred only modest OS gains over time among patients aged older than 75 years, study results showed.Source: Healio
Yale-led Study Seeks to Understand How PET Imaging is Touching the Lives of Patients with Prostate Cancer
Although PET imaging is more accurate at identifying cancer, it is still not known how that accuracy will affect treatments, and whether localization will improve outcomes for patients. To help answer these questions, Yale Urology Associate Professor Michael Leapman, MD, MHS, is leading a collaborative study.
Oncology Therapy at the End of Life: Have We Missed the Mark?
In a study published today in JAMA Oncology, researchers at Yale Cancer Center in collaboration with researchers from Flatiron Health, Inc., revealed that despite recommendations, aggressive cancer care at the end-of-life persists and there has been a substantial transition from the use of chemotherapy to immunotherapy.
Acceptance of Medicaid Varies Greatly among Cancer Care Facilities
Although the number of Americans insured through Medicaid has increased during the past decade, barriers to cancer care access exist among Medicaid beneficiaries across high-quality centers, according to study results in JAMA Network Open.Source: Healio
Services Widely Differ for Patients With Cancer Who Have Medicaid Coverage
Though number of United States residents insured through Medicaid has increased significantly over previous years, barriers to accessing cancer care still exist at high-quality centers, according to data published in the JAMA Network Open journal.Source: Targeted Oncology
Gross, Jonas, O’Connor Elected to AAP
Three faculty members from the Department of Internal Medicine, Cary Gross, MD; Elizabeth Jonas, MD; and Patrick G. O'Connor, MD, MPH, MACP, were elected into the Association of American Physicians (AAP) during the organization’s annual meeting in April 2022.